title: Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
authors: Klaus
authors: K
authors: Bendtzen
mesh_terms: D000068879:Adalimumab; D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000235:genetics / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D055261:Immunogenetic Phenomena / Q000235:genetics / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000009:adverse effects*; D015994:Incidence; D008727:Methotrexate / Q000627:therapeutic use; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D008727:Methotrexate